GeneGo Expands License with Johnson & Johnson
News Feb 21, 2006
GeneGo, Inc. has announced that Johnson & Johnson Pharmaceutical Research & Development, (J&JPRD), a division of Janssen Pharmaceutica N.V., has extended their MetaCore™ license to now include MetaBase™, a database J&JPRD will primarily use for biomarker discovery.
"We are pleased to have this relationship extended," said Julie Bryant, Vice President of Business Development at GeneGo. "We look forward to enhancing our collaboration with the MetaBase integration."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.